McKesson Corporation vs Paychex, Inc. — how do they compare? McKesson Corporation trades at $930 (market cap $108.46B), while Paychex, Inc. trades at $104.29 (market cap $37.19B). The key difference: McKesson Corporation is far larger — about 2.9× Paychex, Inc.'s market cap, and Paychex, Inc. pays the higher dividend (4.56%). Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and Paychex, Inc. for 56 Days on average.
| MCK | PAYX | |
|---|---|---|
Market Cap | $108.46B | $37.19B |
Volume | 712,607 | 3,344,316 |
Sector | Health | Industrials |
52-Week High | $995.69 | $128.59 |
52-Week Low | $725.17 | $85.57 |
Typical Hold Time | 74 Days | 56 Days |
Enterprise Value | $115.00B | $40.87B |
Dividend Yield | 0.4% | 4.56% |
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $910.33, down 1.23% today, but maintains strong analyst support with 80.65% buy ratings and a $956.43 consensus price target. The stock shows bullish technical momentum with recent earnings beats and a major distribution agreement extension with CVS Health through 2032. Revenue growth has accelerated from $264B in 2022 to $359B in 2025, though net margins remain thin at 1.12%.
MCK presents a compelling growth story with consistent earnings outperformance and strategic partnerships driving long-term visibility. However, investors face risks from margin compression, drug pricing pressures, and high leverage with negative shareholder equity. The current valuation at 24.42x P/E appears reasonable given the company's market leadership and oncology growth prospects.
Paychex (PAYX) trades at $101.55, up 0.52% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 27.35% net income margin and a 47.06% ROE, but valuation metrics like a P/E of 20.15 and P/S of 5.52 suggest a premium. Recent news highlights concerns over dividend sustainability and a 14% stock decline, even as the company reported double-digit earnings growth driven by PEO and insurance segments.
The outlook is mixed: solid fundamentals and a consensus price target of $111.00 imply upside, but bearish technicals and investor skepticism about growth levers like AI pose risks. Key opportunities include consistent dividend payments and market leadership, while risks involve labor market sensitivity and high debt levels following a significant increase in total liabilities.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →